Literature DB >> 26830548

Reduction of proteinuria by therapeutic intervention improves the renal outcome of elderly patients with IgA nephropathy.

Yusuke Okabayashi1, Nobuo Tsuboi2, Kotaro Haruhara1, Go Kanzaki1, Kentaro Koike1, Akihiro Shimizu1, Yoichi Miyazaki1, Iwao Ohno1, Tetsuya Kawamura1, Makoto Ogura1, Takashi Yokoo1.   

Abstract

BACKGROUND: The number of elderly patients with IgA nephropathy (IgAN) is increasing in parallel with the increased longevity in the general population. However, information is limited regarding the characteristics of such patients.
METHODS: IgAN patients who were ≥60 years of age at diagnosis were retrospectively analyzed. The clinicopathological features at biopsy, therapies during the follow-up period, renal outcomes and extrarenal complications were evaluated.
RESULTS: The characteristics of a total of 87 patients were as follows (mean values): 65 years of age, an eGFR of 47 mL/min/1.73 m2, and urinary protein excretion (UPE) of 1.9 g/day. In the initial 1-year follow-up period, UPE decreased from 2.4 to 0.4 g/day in patients treated with corticosteroids and 1.4 to 0.8 g/day in patients treated with conservative therapies, including renin-angiotensin system blockade. During the observation period, 26 % of the patients who received corticosteroids and 38 % of the patients treated with conservative therapies showed a ≥30 % decrease in their eGFR or reached end-stage renal disease. In the analysis of all patients, UPE at 1 year after the diagnosis was identified to be an independent predictor of the subsequent loss of renal function. However, neither corticosteroid therapy nor conservative therapies was identified to be an independent valuable. There was no significant difference in the incidence of the extrarenal complications between patients treated with corticosteroids and those with conservative therapies.
CONCLUSION: In elderly IgAN patients, the reduction of proteinuria by therapeutic interventions may lead to better renal outcomes without causing severe extrarenal complications.

Entities:  

Keywords:  Elderly; IgA nephropathy; Proteinuria; Renal biopsy

Mesh:

Substances:

Year:  2016        PMID: 26830548     DOI: 10.1007/s10157-016-1239-y

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  24 in total

Review 1.  Aging promotes progression of IgA nephropathy: a systematic review and meta-analysis.

Authors:  Zhi-Yu Duan; Guang-Yan Cai; Yi-Zhi Chen; Shuang Liang; Shu-Wen Liu; Jie Wu; Qiang Qiu; Shu-Peng Lin; Xue-Guang Zhang; Xiang-Mei Chen
Journal:  Am J Nephrol       Date:  2013-09-10       Impact factor: 3.754

Review 2.  Corticosteroid therapy in IgA nephropathy.

Authors:  Jicheng Lv; Damin Xu; Vlado Perkovic; Xinxin Ma; David W Johnson; Mark Woodward; Adeera Levin; Hong Zhang; Haiyan Wang
Journal:  J Am Soc Nephrol       Date:  2012-04-26       Impact factor: 10.121

3.  Characteristics of IgA nephropathy in advanced-age patients.

Authors:  Yasuko Oshima; Takahito Moriyama; Mitsuyo Itabashi; Takashi Takei; Kosaku Nitta
Journal:  Int Urol Nephrol       Date:  2014-11-12       Impact factor: 2.370

Review 4.  The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines--application to the individual patient.

Authors:  Jai Radhakrishnan; Daniel C Cattran
Journal:  Kidney Int       Date:  2012-08-15       Impact factor: 10.612

5.  IgA nephropathy: prognostic classification of end-stage renal failure. L'Association des Néphrologues de l'Est.

Authors:  L Frimat; S Briançon; D Hestin; B Aymard; E Renoult; T C Huu; M Kessler
Journal:  Nephrol Dial Transplant       Date:  1997-12       Impact factor: 5.992

6.  The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility.

Authors:  Ian S D Roberts; H Terence Cook; Stéphan Troyanov; Charles E Alpers; Alessandro Amore; Jonathan Barratt; Francois Berthoux; Stephen Bonsib; Jan A Bruijn; Daniel C Cattran; Rosanna Coppo; Vivette D'Agati; Giuseppe D'Amico; Steven Emancipator; Francesco Emma; John Feehally; Franco Ferrario; Fernando C Fervenza; Sandrine Florquin; Agnes Fogo; Colin C Geddes; Hermann-Josef Groene; Mark Haas; Andrew M Herzenberg; Prue A Hill; Ronald J Hogg; Stephen I Hsu; J Charles Jennette; Kensuke Joh; Bruce A Julian; Tetsuya Kawamura; Fernand M Lai; Lei-Shi Li; Philip K T Li; Zhi-Hong Liu; Bruce Mackinnon; Sergio Mezzano; F Paolo Schena; Yasuhiko Tomino; Patrick D Walker; Haiyan Wang; Jan J Weening; Nori Yoshikawa; Hong Zhang
Journal:  Kidney Int       Date:  2009-07-01       Impact factor: 10.612

7.  Remission of proteinuria improves prognosis in IgA nephropathy.

Authors:  Heather N Reich; Stéphan Troyanov; James W Scholey; Daniel C Cattran
Journal:  J Am Soc Nephrol       Date:  2007-10-31       Impact factor: 10.121

8.  A tricontinental view of IgA nephropathy.

Authors:  Colin C Geddes; Virpi Rauta; Carola Gronhagen-Riska; Lukasz P Bartosik; Alan G Jardine; Lloyd S Ibels; York Pei; Daniel C Cattran
Journal:  Nephrol Dial Transplant       Date:  2003-08       Impact factor: 5.992

9.  Revised equations for estimated GFR from serum creatinine in Japan.

Authors:  Seiichi Matsuo; Enyu Imai; Masaru Horio; Yoshinari Yasuda; Kimio Tomita; Kosaku Nitta; Kunihiro Yamagata; Yasuhiko Tomino; Hitoshi Yokoyama; Akira Hishida
Journal:  Am J Kidney Dis       Date:  2009-04-01       Impact factor: 8.860

10.  The improvement of renal survival with steroid pulse therapy in IgA nephropathy.

Authors:  Ritsuko Katafuchi; Toshiharu Ninomiya; Tohru Mizumasa; Kiyoshi Ikeda; Harumitsu Kumagai; Masaharu Nagata; Hideki Hirakata
Journal:  Nephrol Dial Transplant       Date:  2008-07-20       Impact factor: 5.992

View more
  6 in total

1.  Total Nephron Number and Single-Nephron Parameters in Patients with IgA Nephropathy.

Authors:  Hirokazu Marumoto; Nobuo Tsuboi; Vivette D D'Agati; Takaya Sasaki; Yusuke Okabayashi; Kotaro Haruhara; Go Kanzaki; Kentaro Koike; Akira Shimizu; Tetsuya Kawamura; Andrew D Rule; John F Bertram; Takashi Yokoo
Journal:  Kidney360       Date:  2021-03-10

2.  Immunosuppressive therapy for active IgA nephropathy is effective and safe, even in "elderly" patients.

Authors:  Michio Fukuda; Osamu Hotta; Masashi Mizuno; Yoshiaki Ogiyama; Nobuyuki Ohte
Journal:  Clin Exp Nephrol       Date:  2016-07-21       Impact factor: 2.801

3.  Do you recommend tonsillectomy for elderly patients with IgA nephropathy?

Authors:  Tsuyoshi Takashima; Masato Mizuta; Yuki Ikeda; Makoto Fukuda; Motoaki Miyazono
Journal:  Clin Exp Nephrol       Date:  2021-03-05       Impact factor: 2.801

Review 4.  Beyond chronic kidney disease: the diagnosis of Renal Disease in the Elderly as an unmet need. A position paper endorsed by Italian Society of Nephrology (SIN) and Italian Society of Geriatrics and Gerontology (SIGG).

Authors:  Filippo Aucella; Andrea Corsonello; Dario Leosco; Giuliano Brunori; Loreto Gesualdo; Raffaele Antonelli-Incalzi
Journal:  J Nephrol       Date:  2019-01-18       Impact factor: 3.902

5.  Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort.

Authors:  Suceena Alexander; Santosh Varughese; Rajanbabu Franklin; Grace Rebekah; Sanjeet Roy; Sabina Yusuf; Athul Thomas; Jeethu Joseph Eapen; Elenjickal Elias John; Anna T Valson; Vinoi George David; Mohamed R Daha; John Feehally; Jonathan Barratt; George T John
Journal:  Kidney Int Rep       Date:  2021-11-24

6.  Distribution of nephrologists and regional variation in the clinical severity of IgA nephropathy at biopsy diagnosis in Japan: a cross-sectional study.

Authors:  Yusuke Okabayashi; Nobuo Tsuboi; Hoichi Amano; Yoichi Miyazaki; Tetsuya Kawamura; Makoto Ogura; Ichiei Narita; Toshiharu Ninomiya; Hitoshi Yokoyama; Takashi Yokoo
Journal:  BMJ Open       Date:  2018-10-31       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.